Stocks to watch next week: Broadcom, Lululemon, British American Tobacco, Dr Martens and Rémy Cointreau
Tariffs remain in focus as earnings season continues to wind down, but there are still a number of key companies due to report in the coming week.
On the back of a strong set of results from chipmaking giant Nvidia (NVDA), attention will now turn to rival Broadcom (AVGO), which is due to report on Thursday.
Athletics wear company Lululemon (LULU) is also due to report on Thursday, with focus on its outlook for the current year, after guidance offered at the end of the last financial year failed to impress investors.
In London, investors will want to see if British American Tobacco (BATS.L) has continued to generate sales growth from its new categories business, which includes vapes and heated products.
Investors will also be keen to see how Dr Martens (DOCS.L) turnaround efforts are progressing when the iconic bootmaker reports its full-year results on Thursday.
On the Paris bourse, Rémy Cointreau's (RCO.PA) full-year performance will be in focus, ahead of a new CEO taking the helm at the French spirits company later in June.
Here's more on what to look out for:
Shares in Nvidia (NVDA) jumped after it reported another blowout quarter on Wednesday, despite the company warning of the impact of export controls that limit its ability to ship products to China.
The chipmaker posted revenue of $44.1bn (£32.7bn) for the first quarter, beating expectations of $43.3bn, though earnings per share of $0.81 came in below estimates of $0.93.
Derren Nathan, head of equity analysis at Hargreaves Lansdown, said: "The first key takeaway from Nvidia's (NVDA) Q1 print was that demand for accelerated computing remains extremely strong due to the lightning speed roll out of AI. The second is that Nvidia remains the dominant force in this market."
"However, with McKinsey predicting a spend of around $7tn to help data centres keep pace with processing demands out to 2030, the market is big enough to accommodate more than just one player," he added. "Broadcom's (AVGO) custom ASIC chips can help hyperscalers lower their average cost of data processing and as such it looks well set to grow its share of the market."
Read more: What's behind the surge in AI-related lawsuits?
Nathan said that consensus forecasts for Broadcom's (AVGO) second quarter revenue are broadly in line with the company's guidance of approximately $14.9bn, which works out to growth of around 19%.
He highlighted that artificial intelligence (AI) is a "growing share of Broadcom's (AVGO) revenue base but there's still more sales coming from non-AI workloads leaving the company exposed to cyclical ups and downs, which is a risk in today's macroeconomic environment. And with 20% of revenue coming from China, markets will be keen to hear the potential impact of export restrictions and tariffs."
Nathan added that estimates for Broadcom's (AVGO) third quarter revenue have been falling slightly over the last month and currently stand at $15.8bn. "But with so many moving parts to the picture the company's steer will be a key metric to focus on," he said.
Broadcom (AVGO) shares popped after the company posted first quarter results in March that beat on the top and bottom lines, driven by AI chip sales. Adjusted net revenue came in at $14.92bn, versus expectations of $14.61bn, while adjusted earnings per share of $1.60 were ahead of estimates of $1.50. However, fluctuations in the stock since then have left it up just 4.4% year-to-date.
Shares in Lululemon (LULU) sunk after its earnings outlook appeared to underwhelm investors, despite the company posting better-than-expected quarterly profits in March.
The athletics wear retailer said it expected earnings per share for this year to be in the range of $14.95 to $15.15, which was below expectations of $15.37. On revenue, the company said it expected this to be in the range of $11.15bn to $11.3bn.
In addition, Lululemon (LULU) chief financial officer (CFO) told investors on an earnings call that the company was not expecting store traffic to improve this year versus softness out of the gate in the first quarter.
Read more: Stocks that are trending today
In a note on 12 May, Barclays analysts – which had an "equal weight" rating on Lululemon (LULU) – said they were "cautious" on the stock.
They highlighted that the retailer's "We Made Too Much" online clearance section "showed an increase towards the end of the quarter".
"During 1Q25, the WMTM category negatively inflected in the final few weeks of the quarter," they said.
They said this suggested "potential for weaker exiting trends and building inventory risk".
For the first quarter, Lululemon (LULU) said it expected net revenue to come in between $2.34bn and $2.36bn, which would represent growth of 6% to 7%. Diluted earnings per share are expected to be in the range of $2.53 to $2.58 for the quarter.
On Wednesday, British American Tobacco (BATS.L) announced that it had sold a 2.5% stake in Indian consumer goods company ITC (ITC.NS), which was worth $1.5bn, according to a Reuters report.
The company said that the transaction would give it "greater financial flexibility as it delivers on its commitment to invest behind transformation, deleverage and enhance shareholder returns."
The tobacco giant also said that the net proceeds from the trade would be used to extend its existing share buyback programme by an additional £200m ($269.5m), taking the total amount it repurchases in 2025 to £1.1bn.
That was up on £900m BAT (BATS.L) said it planned to undertake in buybacks this year back in its preliminary results release in February.
Shares tumbled after the release of those results, in which the company flagged £6.2bn ($7.7bn) hit, from a proposed settlement of a long-running lawsuit in Canada. With this provision, the company posted reported profit from operations for the year of £2.74bn.
Read more: Government 'megafund' pension plans could give £6k boost to savers
BAT (BATS.L) posted a 5.2% decline in reported revenue for the year at £25.9bn, driven by the sale of its businesses in Russia and Belarus in September 2023 and transnational foreign exchange headwinds. However, the company saw 8.9% organic growth from revenue in its new categories business at £3.4bn.
Nathan, of Hargreaves Lansdown, said that the company "heads into its upcoming [first-half] trading update with investor attention firmly on its ability to navigate persistent industry headwinds".
"Regulatory pressures and rising tobacco taxes continue to weigh on the outlook," he said.
"As such, this year's guidance for around 1% sales growth and 1.5–2.5% profit growth currently stands below the group's medium-term targets. The upcoming update will be closely watched for signs that 'new categories' can deliver more meaningful growth and help offset the structural decline in traditional tobacco."
In addition, Nathan said that investors "will be watching closely to see if US action to crackdown on illegal competition has had any impact and whether the lifting of a proposed ban on menthol cigarettes has helped the outlook".
According to consensus forecasts provided by the company on its website, analysts expect full-year total revenue for 2025 to come in at £26.2bn, including £3.88bn from new category business.
Shortly after taking over as Dr Martens (DOCS.L) CEO in January, Ije Nwokorie said in a third quarter trading update that the bootmaker had made "good progress" on turning round performance in the US.
He said that the team were focused on "returning the business to sustainable and profitable growth".
In the third quarter, Dr Martens (DOCS.L) reported 3% growth in group revenue at £267m, with a 4% increase in direct-to-consumer business in the Americas.
"Dr Martens (DOCS.L) is expected to deliver more evidence that it is pulling itself up by its bootstraps and the turnaround is lacing together," said Susannah Streeter, head of money and markets at Hargreaves Lansdown. "It's been reducing inventories and debt, preserving cash and stabilising the business overall."
Stocks: Create your watchlist and portfolio
"The iconic footwear company has found it hard going stomping new fashion ground overseas, with the US, its biggest market, proving particularly tough," she said. "But in the key autumn/winter season, there were signs that increased investment in marketing was paying off, with new styles winning fans. It's trying to get the heritage models and new innovations in the fashion market."
Streeter said that the "performance of the last quarter will be a test" for new CEO Nwokorie.
She said that the company's "strategy includes new store roll outs and increasing the direct-to-consumer mix, as well as improving the quality and depth of wholesale distribution.
"It's hoped that the Docs will also take a step forward with the appointment of a new chief brand officer, Carla Murphy, a former Adidas (ADS.DE) global executive who also has experience at VF Corporation, the American global apparel and footwear company."
In its January trading update, company didn't offer specifics on its guidance for the full year but said its outlook remained unchanged and that it was on track to achieve its objectives. Despite signs of turnaround progress, the stock is still down nearly 19% year-to-date.
French cognac maker Rémy Cointreau (RCO.PA) announced on Wednesday that it had appointed Franck Marilly as the company's new CEO, taking over from Eric Vallat, who said last month he would be stepping down.
Marilly, who assumes the role on 25 June, has previously worked for Japanese beauty brand Shiseido (4911.T), luxury fashion house Chanel and consumer goods giant Unilever (ULVR.L).
The news comes as Rémy Cointreau (RCO.PA) navigates challenges around trade tensions with both the US and China, two of its key markets.
In a fourth quarter sales update in April, Rémy Cointreau (RCO.PA) posted an 18% fall in full-year sales at €984.6m (£827.6m). The company flagged a "steep decline" in sales of cognac in China in the fourth quarter, which it said was partly down to "harsh market conditions", among other factors.
Read more: UK 'bargain' stocks that have outperformed the market long-term
In January, China launched an anti-dumping investigation on brandy imported from the European Union (EU), which was extended in April and included the imposing of temporary duties on imports of brandy. The probe was considered to be in response to EU duties on Chinese electric vehicles.
Rémy Cointreau (RCO.PA) said in its April sales update that if the provisional duties were confirmed, the company would "trigger its action plan to mitigate the effects starting in fiscal 2025-26. The impact on fiscal year 2024-25 is marginal."
In addition, there is also uncertainty around US tariffs on the EU, with talks between the two ongoing, after president Donald Trump hit pause on his threat to impose 50% duties on the bloc.
Investors will be looking at Rémy Cointreau's (RCO.PA) final full-year results on Wednesday for any commentary around the potential impact of these tariff challenges in the year ahead.
The company said in April that a €50m (£42m) cost-cutting plan would help protect its operating margin, expecting this to come in between 21% and 22% for the year. It also reiterated its financial targets for 2029-30 of hitting a gross margin of 72% and an operating margin of 33%.
Monday 2 June
Sirius Real Estate (SRE.L)
Campbell's Co (CPB)
Tuesday 3 June
Chemring (CHG.L)
Pennon (PNN.L)
Gooch & Housego (GHH.L)
Crowdstrike Holdings Inc (CRWD)
Ferguson Enterprises Inc (FERG)
Dollar General Corp (DG)
Hewlett Packard Enterprise (HPE)
Nio Inc (NIO)
Signet Jewelers (SIG)
Wednesday 4 June
Paragon Banking (PAG.L)
B&M European Value Retail (BME.L)
DiscoverIE (DSCV.L)
Ramsdens (RFX.L)
Dollar Tree Inc (DLTR)
GameStop (GME)
Thursday 5 June
Mitie (MTO.L)
Workspace (WKP.L)
Young's & Co Brewery (YNGN.L)
Fevertree (FEVR.L)
Fastenal (FAST)
DocuSign (DOCU)
Brown-Forman (BF-B)
Ciena (CIEN)
Wizz Air Holdings (WIZZ.L)
CMC Markets (CMCX.L)
Friday 6 June
ABM Industries Inc (ABM)
Caffyns (CFYN.L)
You can read Yahoo Finance's full calendar here.
Read more:
How getting ahead on your tax return can help cut your tax bill
Odds of more Bank of England interest rate cuts fall as food inflation rises
Trump tariffs to hit UK economy next year, says IMF

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Sanofi to acquire Blueprint for up to $9.5B
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint's research revolves around an enzyme made by a gene called KIT. This 'tyrosine kinase' enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases. Blueprint already has one medicine approved by the Food and Drug Administration, Ayvakit, and is working on a handful of others, two of which are in human testing. The FDA first approved Ayvakit in early 2020 for a rare kind of hard-to-treat gastrointestinal tumor, and specifically for the small subset of adults who have these tumors and certain mutations. Since then, the agency cleared the medicine as a treatment for both the less and more aggressive forms of 'systemic mastocytosis,' an uncommon disorder where a kind of white blood cell known as a mast cell builds up in the bone marrow, digestive tract, skin and other organs. The accumulation can lead to severe inflammation and organ damage. Last year, Blueprint posted $479 million in net product revenue from Ayvakit. The company used to have another marketed cancer drug, Gavreto, which it was co-developing and commercializing with Roche. But Roche ultimately backed away from that alliance, leading Blueprint to sell away rights to Rigel Pharmaceuticals in early 2024. In a statement announcing the deal, Sanofi highlighted the recent trajectory in Ayvakit sales. They were up more than 60%, for example, between the first quarter of 2024 and the same three-month period this year. Blueprint recorded a $67 million net loss in 2024, compared to a more than half-a-billion-dollar net loss in each of the previous two years. The proposed acquisition 'represents a strategic step forward in our rare and immunology portfolios,' Sanofi CEO Paul Hudson said in the Monday statement. 'It enhances our pipeline and accelerates our transformation into the world's leading immunology company.' Hudson added that his company maintains a 'sizeable capacity for further acquisitions.' After being an active dealmaker over the past few years, the French pharmaceutical giant still had close to 8 billion euros in cash and cash equivalents at the end of March. Sanofi bought the diabetes drug developer Provention Bio for almost $3 billion in 2023 and the rare disease-focused Inhibrix for $2.2 billion in 2024. And just last month, it agreed to spend $470 million on Vigil Neuroscience, a Massachusetts-based biotechnology company touting an Alzheimer's disease drug that just finished an early-stage human study. Similar to its Vigil proposal, Sanofi is offering Blueprint investors a so-called contingent value right that could be worth up to $6 per Blueprint share, provided one of the biotech's experimental drugs, 'BLU-808,' hits certain development and regulatory goals. BLU-808 is in mid-stage testing as a possible treatment for chronic hives and an allergy-related condition that causes runny eyes and a congested nose. Blueprint also believes the drug could be useful in treating allergic asthma and 'mast cell activation syndrome.' Another Blueprint drug, elenestinib, is further along, having advanced to a late-stage study for the slower-moving form of systemic mastocytosis. Sanofi's upfront payment of $9.1 billion values Blueprint shares at $129 apiece, reflecting a premium of about 27% from the biotech's closing stock price on Friday. The transaction is expected to close sometime between July and the end of September, according to Sanofi. Andrew Berens, an analyst at the investment firm Leerink Partners, wrote in a note to clients how his team expected Blueprint to land on the 'strategic radar of large pharma' given Ayvakit is on the path to $1 billion or more in annual sales and the company recently raised its financial guidance for this year. However, the deal came sooner than anticipated, ahead of a key data readout for a rival drug from Cogent Biosciences. Cogent's bezuclastinib is also being evaluated as a treatment for systemic mastocytosis, with results set to arrive in the next couple months. Regardless of how strong or weak those results will be, Berens believes they'd serve as a tailwind for Blueprint 'by removing a key overhang and allowing a strategic acquirer to structure a deal based on assumptions about ... market dynamics.' As such, Cogent's data could have propped up Blueprint's share price, 'which may have been an impetus for Sanofi to do the deal now,' Berens posited. Even so, the analyst still sees Sanofi's bid as a positive for Blueprint and this field of research. Cogent shares were down by about 2% late Monday morning. Recommended Reading Blueprint wins key FDA approval for rare disease drug Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
France Charges 25 People, Including 6 Minors, in Crypto Kidnapping Cases
French authorities have charged 25 people, including six minors, for their roles in a spate of crypto kidnappings in Paris, with the majority of the suspects connected to the recent failed kidnapping attempt of a crypto exchange CEO's family, Paris's public prosecutor's office said, Le Monde reported Saturday. The investigation is focused on the kidnapping attempt of the daughter and grandson of the CEO of crypto exchange Paymium, Pierre Noizat, that occurred on May 13, the report said. The probe also looked at other unsuccessful kidnapping attempts, including an earlier attempt on Noizat's family members, plus an attempted abduction near the western city of Nantes last Monday that authorities thwarted. The arrests follow a spate of high-profile crypto kidnappings that have plagued France this year. In May the father of a French crypto millionaire was kidnapped, the BBC reported. At the start of the year David Ballard, a co-founder of crypto-wallet developer Ledger was kidnapped alongside his wife. Both of the men had a finger severed, with videos of the appendage used to extract a ransom. Following the recent kidnappings France's Minister of the Interior Bruno Retailleau hosted a meeting with crypto stakeholders in May to discuss measures to keep them secure. The suspects involved in the May 13 case were between the ages of 16 and 23 years; six of them were minors, the Le Monde report said. They were mostly born in France while three individuals were from Senegal, Angola and Russia, the report cited prosecutors as saying. This case is characterized by "very young profiles, lured by money and then caught up in a situation that is beyond them," observed lawyer Ambroise Vienet-Legué, who is defending an 18-year-old suspect in the Nantes part of the case, the report said. A source familiar with the investigation told CoinDesk that the suspects are believed to be locally-hired muscle, who are paid by a criminal operation in Southeast Asia to carry out the kidnappings for as little as $10,000. Eighteen people are in pre-trial detention, three have requested a deferred hearing while four are under judicial supervision, the public prosecutor said. Though France has been the epicenter of crypto kidnappings, similar crimes are on the rise across the globe, including recent several cases in the U.S. CoinDesk reached out to Paris's prosecution office for a comment.

USA Today
an hour ago
- USA Today
Kim Kardashian's Skims launched viral nipple bras. Hips are next.
Kim Kardashian's Skims launched viral nipple bras. Hips are next. Show Caption Hide Caption Several convicted in Kim Kardashian's 2016 robbery Several individuals were convicted of robbing Kim Kardashing in her hotel room during Paris Fashion Week in 2016. Kim Kardashian's next viral Skims product is shaping up to be the ultimate hit. The "ultimate hips" by Kardashian's billion-dollar shapewear brand are designed with soft foam pads embedded at the hip to form an hourglass figure that accentuates a person's curves. The hips are shaped at the mid-thigh with elastic along the waist and feature a raw cut leg opening, according to a press release from Skims. Kardashian's ultimate hip shapewear will run for $108 and will be available for purchase on Thursday, June 5. The product harkens back to another Skims item. In October 2023, Kardashian released nipple bras, which combined climate change awareness with sex appeal. Despite criticism and mockery, the nipple bras found a loyal community of people who have or had breast cancer and lost their nipples in an attempt to save their lives. That year, the nipple push-up bra sold out and was restocked on the Skims website multiple times. The latest Skims innovation launches shortly after suspects in Kim Kardashian's French robbery trial were found guilty on May 23. Kim Kardashian graduates law program, following in footsteps of lawyer dad Robert Kardashian The mixed panel of judges and jury convicted eight of the 10 defendants for crimes directly linked to the theft, while another defendant was found guilty of illegal weapons charges. One person was acquitted. The heaviest sentences were handed down to five defendants who participated directly in the heist, with the robbery mastermind Khedache receiving a three-year jail sentence. Days earlier, the burgeoning actress revealed to fans that she had completed her four-year Law Office Study Program and shared videos of an intimate backyard ceremony surrounded by family and friends. Her late father was a defense attorney for the defense in former NFL player O.J. Simpson's murder trial.